V1RB8 inhibitors are a class of chemical compounds designed to selectively interact with a specific subset of receptors known as V1RB8. These receptors are part of a larger family of receptors that play a critical role in various molecular signaling pathways within the body. The V1RB8 receptor, like its family members, is a protein that spans the cellular membrane and is involved in transmitting signals from the outside to the inside of the cell. Inhibitors that target these receptors do so by binding to them in a way that prevents their normal function, effectively blocking the receptor's ability to interact with its natural ligands. This binding interaction is highly specific, taking advantage of the unique structure of the V1RB8 receptor to ensure selectivity and minimize off-target effects.
The design and development of V1RB8 inhibitors require a deep understanding of the receptor's biochemistry and structure. Advanced techniques such as X-ray crystallography, cryo-electron microscopy, and molecular modeling often contribute to mapping the three-dimensional shape of the receptor, which is critical for the design of an effective inhibitor. These compounds are typically characterized by their binding affinity, which is a measure of how strongly they interact with the receptor, and their selectivity, which indicates how exclusively they bind to the V1RB8 receptor over other related receptors. Inhibitors are also evaluated based on their pharmacokinetic properties, which include their absorption, distribution, metabolism, and excretion (ADME) profiles. These properties are essential to understand the behavior of the inhibitors once they interact with the receptor and their subsequent fate within the biological system. The chemical structure of V1RB8 inhibitors is often complex, with a careful balance between hydrophobic and hydrophilic elements, enabling them to cross cellular membranes and reach their target receptor while remaining stable and active within the biological environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Alprenolol is a non-selective beta-adrenergic receptor antagonist that can indirectly inhibit V1RB8 by reducing the adrenergic activity that may be upstream or parallel to V1RB8 signaling. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, a selective estrogen receptor modulator, can indirectly affect V1RB8 activity by altering estrogen receptor-mediated signaling pathways that potentially intersect with V1RB8's role in modulating social behaviors. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist, which may indirectly inhibit V1RB8 by modulating serotonergic signaling pathways that could influence the same neuronal circuits as V1RB8. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol, a dopamine antagonist, could indirectly inhibit V1RB8 activity by affecting dopaminergic signaling pathways, which may interact with V1RB8 in the regulation of social and emotional behaviors. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist that could potentially inhibit V1RB8 by affecting the renin-angiotensin system, which may have a regulatory relationship with V1RB8-mediated effects. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker that can lead to the indirect inhibition of V1RB8 by affecting intracellular calcium levels, which are critical for the signaling cascades V1RB8 may be involved in. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a beta-blocker that might indirectly inhibit V1RB8 by attenuating beta-adrenergic signaling, which could modulate the same physiological processes as V1RB8. | ||||||
Clonidine | 4205-90-7 | sc-501519 | 100 mg | $240.00 | 1 | |
Clonidine, an alpha-2 adrenergic agonist, may indirectly inhibit V1RB8 by modulating adrenergic activity, potentially affecting the neuromodulatory pathways that V1RB8 is involved in. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Sodium Valproate, a GABAergic agonist, could indirectly inhibit V1RB8 by enhancing GABAergic inhibition, which might influence the neuronal circuits where V1RB8 is active. | ||||||
Carbamazepine | 298-46-4 | sc-202518 sc-202518A | 1 g 5 g | $33.00 $71.00 | 5 | |
Carbamazepine, a sodium channel blocker, may indirectly inhibit V1RB8 by affecting neuronal excitability and thus potentially modulating the neural pathways that V1RB8 influences. | ||||||